DOI: 10.1161/jaha.126.052821 ISSN: 2047-9980

Physical Activity and Cardiovascular Risk in Type 2 Diabetes With Normal Body Mass Index and Abdominal Obesity: A Nationwide Cohort Study

Onyou Kim, Yong Hwan Park, Soo Yeon Kim, Myeongcheol Lee, Wonchang Hahn, Chang Hoon Kim, Danbee Kang, Ki Hong Choi
Show PDF Cite

Background

The prognostic implications of abdominal obesity and moderate‐to‐vigorous physical activity (MVPA) in patients with type 2 diabetes who have a normal body mass index remain unclear.

Methods

This nationwide retrospective cohort study included 323 029 adults with newly diagnosed type 2 diabetes and a normal body mass index (<23 kg/m 2 ) between January 1, 2010, and December 31, 2023, from the Korean National Health Insurance Service database. Abdominal obesity was defined using sex‐specific waist circumference thresholds (≥90 cm for men, ≥80 cm for women). MVPA was assessed through standardized self‐reported questionnaires administered during routine health screenings. The primary outcome was major adverse cardiovascular and cerebrovascular events, defined as a composite of all‐cause death, myocardial infarction, ischemic stroke, or hospitalization for heart failure.

Results

Among the study population, 34 033 (10.5%) had abdominal obesity. During a median follow‐up of 6.0 years (interquartile range, 2.6–9.0 years), abdominal obesity was associated with a higher risk of major adverse cardiovascular and cerebrovascular events (adjusted hazard ratio [HR], 1.13 [95% CI, 1.09–1.17]). Among patients with abdominal obesity, regular MVPA after diagnosis (27.1%) was associated with a significantly lower risk of major adverse cardiovascular and cerebrovascular events (adjusted HR 0.74 [95% CI, 0.68–0.80]), all‐cause mortality (adjusted HR 0.72 [95% CI, 0.65–0.80]), ischemic stroke (adjusted HR 0.77 [95% CI, 0.66–0.89]), and hospitalization for heart failure (adjusted HR 0.75 [95% CI, 0.60–0.93]). The cardiovascular protective effects of MVPA were consistent regardless of statin or antidiabetic medication use.

Conclusions

In patients with type 2 diabetes and a normal body mass index, abdominal obesity was independently associated with a higher risk of major adverse cardiovascular and cerebrovascular events. Regular engagement in MVPA showed consistent cardiovascular benefits in this population, irrespective of pharmacotherapy.

Registration

URL: https://www.clinicaltrials.gov ; Unique identifier: NCT07071545.

More from our Archive